“…Also, the short half-life of protein drugs and their limited transit time in the gastrointestinal tract represent major challenges (El-Sherbiny, Abdel-Bary, & Harding, 2010;Ramadas, Paul, Dileep, Anitha, & Sharma, 2000). To date, several trials have been reported to overcome these shortcomings and to formulate peptide and protein drugs with maximum oral bioavailability (Dolatabadi-Farahani, Vasheghani-Farahani, & Mirzadeh, 2006;El-Sherbiny et al, 2010;Heller et al, 2002;Imren, Gumusderelioglu, & Guner, 2010;Liu, Jiao, & Zhang, 2007;Mi et al, 2005;Rekha & Sharma, 2008).…”